Investment analysts at Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for shares of OmniAb in a report released on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now ...
Hosted on MSN2d
Leerink Partners Downgrades Accolade (ACCD)Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from ...
Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...
Investment analysts at Zacks Research cut their FY2025 earnings estimates for Zoetis in a research report issued on Wednesday ...
Leerink Partners analyst Andrew Berens maintained a Hold rating on Agios Pharma (AGIO – Research Report) on January 6. The company’s shares ...
Hosted on MSN4d
Leerink Partners Upgrades Align Technology (ALGN)Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (NasdaqGS:ALGN) from ...
On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...
Walgreens Boots Alliance beat analysts' lowered expectations for first-quarter profit and maintained its annual forecast on ...
CureVac BV (CVAC) stock saw a modest uptick, ending the day at $4.44 which represents a slight increase of $0.82 or 22.65% from the prior close of $3.62. The stock opened at $4.14 and touched a low of ...
Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...
Leerink Partners analyst Puneet Souda has maintained their bullish stance on NTRA stock, giving a Buy rating on January 7.Stay Ahead of the ...
Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback